Literature DB >> 14760951

Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite.

J Hobart1, N Kalkers, F Barkhof, B Uitdehaag, C Polman, A Thompson.   

Abstract

We compared the relative measurement precision (RMP) of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) for discriminating between groups of patients known to differ in their extent of multiple sclerosis (MS). A total of 133 patients were rated with the EDSS and MSFC and had magnetic resonance imaging (MRI) scans. Patients were grouped on the basis of MRI appearances (T1- and T2-weighted lesion loads, parenchymal and ventricular fractions--T1LL, T2LL, PF, VF, respectively) and RMP was determined using the method of group differences. For each MRI parameter, the total sample was arranged in ascending order of magnitude and divided into two, three, four and five similar sized groups. For each division (two, three, four or five groups), EDSS and MSFC scores for the groups were compared using parametric (paired samples t-tests, one-way ANOVA) and nonparametric (Wilcoxon's rank-sum test, Kruskal-Wallis analysis of variance) statistical methods and RMP was estimated. The EDSS and MSFC were correlated substantially (r = -0.64). Relative to the MSFC, the EDSS had inferior measurement precision regardless of the number of groups into which the total sample was divided, or the statistical method. However, the RMP of the EDSS compared with the MSFC varied from 2% to 86%. Results suggest the MSCF is better than the EDSS for detecting differences between groups of patients, defined by these MRI markers of MS. However, the finding that both scales correlated weakly with MRI markers, indicated that they are limited as predictors of MS pathology as defined by MRI. An explanation for this well-established clinical-MRI paradox is that rating scales and MRI measure fundamentally different manifestations of MS.

Entities:  

Mesh:

Year:  2004        PMID: 14760951     DOI: 10.1191/1352458504ms983oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  15 in total

1.  Intracortical excitability in patients with relapsing-remitting and secondary progressive multiple sclerosis.

Authors:  A Conte; D Lenzi; V Frasca; F Gilio; E Giacomelli; M Gabriele; C Marini Bettolo; E Iacovelli; P Pantano; C Pozzilli; M Inghilleri
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

2.  Validation of a Spanish version of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis.

Authors:  Gerard Muñoz; Maria Buxó; Javier de Gracia; Casilda Olveira; Miguel Angel Martinez-Garcia; Rosa Giron; Eva Polverino; Antonio Alvarez; Surinder S Birring; Montserrat Vendrell
Journal:  Chron Respir Dis       Date:  2016-02-22       Impact factor: 2.444

3.  Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.

Authors:  Stuart D Cook; Suhayl Dhib-Jalbut; Peter Dowling; Luca Durelli; Corey Ford; Gavin Giovannoni; June Halper; Colleen Harris; Joseph Herbert; David Li; John A Lincoln; Robert Lisak; Fred D Lublin; Claudia F Lucchinetti; Wayne Moore; Robert T Naismith; Carlos Oehninger; Jack Simon; Maria Pia Sormani
Journal:  Int J MS Care       Date:  2012

4.  A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis.

Authors:  J Furby; T Hayton; D Altmann; R Brenner; J Chataway; K J Smith; D H Miller; R Kapoor
Journal:  J Neurol       Date:  2010-05-01       Impact factor: 4.849

5.  How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales.

Authors:  J C Hobart; A Riazi; D L Lamping; R Fitzpatrick; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11       Impact factor: 10.154

Review 6.  Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.

Authors:  Daniel Ontaneda; Robert J Fox; Jeremy Chataway
Journal:  Lancet Neurol       Date:  2015-02       Impact factor: 44.182

7.  Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord.

Authors:  Kathleen M Zackowski; Seth A Smith; Daniel S Reich; Eliza Gordon-Lipkin; BettyAnn A Chodkowski; Divya R Sambandan; Michael Shteyman; Amy J Bastian; Peter C van Zijl; Peter A Calabresi
Journal:  Brain       Date:  2009-03-18       Impact factor: 13.501

8.  A comparison of three measures of upper limb function in Friedreich ataxia.

Authors:  L A Corben; G Tai; C Wilson; V Collins; A J Churchyard; M B Delatycki
Journal:  J Neurol       Date:  2009-10-13       Impact factor: 4.849

9.  Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis.

Authors:  Ellen M Mowry; Emmanuelle Waubant; Charles E McCulloch; Darin T Okuda; Alan A Evangelista; Robin R Lincoln; Pierre-Antoine Gourraud; Don Brenneman; Mary C Owen; Pamela Qualley; Monica Bucci; Stephen L Hauser; Daniel Pelletier
Journal:  Ann Neurol       Date:  2012-08       Impact factor: 10.422

10.  Development and validation of the activity significance personal evaluation (ASPEn) scale.

Authors:  Trudy Mallinson; Stacey L Schepens Niemiec; Mike Carlson; Natalie Leland; Cheryl Vigen; Jeanine Blanchard; Florence Clark
Journal:  Aust Occup Ther J       Date:  2014-10-04       Impact factor: 1.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.